Iluvien® is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.
Rapid Review
| Commenced | Completed | Outcome |
| 15/02/2016 | 01/03/2016 | Full Pharmacoeconomic Evaluation Not Recommended |